Clinical Tolerance and Equivalence of hCG-IBSA vs Recombinant Human Chorionic Gonadotrophin in Women Undergoing In Vitro Fertilisation

Inclusion Criteria: * \>/=18 and \< 40 years old; * BMI between 18 and 30 kg/m2; * less than 3 previous completed cycles; * both ovaries present; * regular menstrual cycle of 25-35 days; * infertility attributable to a tubal factor, American Fertility Society grade I or II endometriosis, male factor or unexplained factor. * within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through hysterosalpingogram, sonohystrogram or hysteroscopic examination; * basal FSH level less than 10 IU/L; * criteria for hCG administration fulfilled (at least 2 follicles with a diameter of 16 mm or more, with acceptable serum E2 concentration). * a male partner with semen analysis within the past 6 months showing acceptable values of seminal parameters, defined as \> 3x10 exp 6 spermatozoa/ml; * qualified to receive 150 - 300 IU FSH as starting dose. Exclusion Criteria: * age \< 18 and \> o = 40 years; * primary ovarian failure or women known as poor responders (i.e. requiring more than 300 IU of FSH as a starting dose in previous treatment cycles or having less than 3 oocytes retrieved, or with an E2 serum concentration \< 3'000 pmol/L); * ovarian cysts \> 20 mm, or enlargement not due to polycystic ovarian syndrome; * patients affected by pathologies associated with any contraindication of being pregnant; * hypersensitivity to the study medication; * any bleeding since stimulation; * uncontrolled thyroid or adrenal dysfunction; * neoplasias; * severe impairment of the renal and/or hepatic functions; * use of concomitant medication that might interfere with study evaluations (e.g. nonstudy hormonal medications, prostaglandin inhibitors, psychotropic agents); * more than 18 days of FSH stimulation.